Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Core Insights - Ventyx Biosciences is advancing its NLRP3 inhibitor portfolio with significant clinical trials expected in 2025, including VTX2735 for recurrent pericarditis and VTX3232 for obesity and cardiometabolic risk factors [1][2][3] Pipeline Updates and Anticipated Milestones - The Phase 2 trial of VTX2735 in recurrent pericarditis is set to begin in January 2025, enrolling approximately 30 participants with topline results anticipated in H2 2025 [3][4] - VTX3232 is currently in a Phase 2 trial for participants with obesity and cardiometabolic risk factors, with an expected enrollment of around 160 subjects and topline results also expected in H2 2025 [3][5] - Ongoing Phase 2 biomarker trial of VTX3232 in early Parkinson's disease is expected to report topline results in H1 2025 [1][6] Financial Position - As of December 31, 2024, Ventyx reported a cash, cash equivalents, and marketable securities balance of $252.9 million, which is projected to fund operations into at least H2 2026 [1][2][12] Company Overview - Ventyx Biosciences focuses on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, leveraging expertise in medicinal chemistry and clinical development [8][10]